enVVeno Medical
NVNO
31 hedge funds and large institutions have $19.8M invested in enVVeno Medical in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 8 closing their positions.
1,965% more call options, than puts
Call options by funds: $4.11M | Put options by funds: $199K
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
11% more funds holding
Funds holding: 28 → 31 (+3)
0.14% less ownership
Funds ownership: 0.92% → 0.78% (-0.14%)
11% less capital invested
Capital invested by funds: $22.2M → $19.8M (-$2.33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.03M |
| 3 |
RAG
RIA Advisory Group
Des Moines,
Iowa
|
+$224K |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$178K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.24M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.77M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.6M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.08M |
| 5 |
Morgan Stanley
New York
|
-$121K |
NVNO Hedge Fund Activity: Q1 2024 in Review
31 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q1 2024, worth a combined $19.8M — down 11% from $22.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NVNO positions and 8 closed out — a net gain of 3 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.22M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.24M sold.
- 31 institutional investors held enVVeno Medical (NVNO) as of Q1 2024, up from 28 in Q4 2023.
- Funds reported $19.8M of enVVeno Medical stock for Q1 2024, down 11% quarter-over-quarter.
- 11 funds opened new enVVeno Medical positions in Q1 2024 and 8 closed out, a net change of +3 holders.
- The largest enVVeno Medical buyer in Q1 2024 was Vanguard Group, an estimated $1.22M added.
- The largest enVVeno Medical seller in Q1 2024 was Armistice Capital, an estimated $2.24M sold.
Based on aggregated 13F filings for Q1 2024.